药物开发 药物开发
Huan Ma1, Yulu Yan1, Zihan Wang1
1The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
DL-3-n-butylphthalide (NBP) 在治疗早发性中风后认知障碍 (PSCI) 中表现有前途. 这项研究发现,NBP在12周后显著降低了PSCI风险,这表明它是潜在的治疗剂.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 脑卒中后认知障碍 (PSCI) 影响了三分之一的中风幸存者,导致严重的残疾和负担.
- 早期发病的PSCI缺乏特定的治疗方法,尽管其患病率很高.
- 来自菜种子的DL-3-n-butylphthalide (NBP) 证明了线粒体的保护和微循环的改善.
研究的目的:
- 研究DL-3-n-丁甲酸 (NBP) 在治疗早发性中风后认知障碍 (PSCI) 的疗效.
主要方法:
- 一项为期24周的盲人临床试验涉及125名45-80岁的参与者,他们患有早期发病的PSCI.
- 参与者被随机分配,接受NBP或常规治疗.
- 在基线和6,12和24周时,使用MoCA尺度评估认知功能.
主要成果:
- 在12周内,NBP治疗与显著降低PSCI患病率有关 (52.6%对75.6%,p=0.029).
- 多变量逻辑回归表明NBP治疗降低了PSCI风险 (OR=0.26,p=0.020),调整为关键共变量.
- 虽然PSCI患病率在两组都下降了,但NBP在12周的标志上显示出明显的好处.
结论:
- 与NBP结合治疗在早期发病的PSCI中加速恢复.
- 在早期发病的PSCI中,NBP显示出作为一种新型治疗剂的潜力.
更多相关视频
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
相关概念视频
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation
